MYC locus rearrangements-often complex combinations of translocations, insertions, deletions and inversions-in multiple myeloma (MM) were thought to be a late progression event, which often did not involve immunoglobulin genes. Yet, germinal center activation of MYC expression has been reported to cause progression to MM in an MGUS (monoclonal gammopathy of undetermined significance)-prone mouse strain. Although previously detected in 16% of MM, we find MYC rearrangements in nearly 50% of MM, including smoldering MM, and they are heterogeneous in some cases. Rearrangements reposition MYC near a limited number of genes associated with conventional enhancers, but mostly with super-enhancers (e.g., IGH, IGL, IGK, NSMCE2, TXNDC5, FAM46C, FOXO3, IGJ, PRDM1). MYC rearrangements are associated with a significant increase of MYC expression that is monoallelic, but MM tumors lacking a rearrangement have biallelic MYC expression at significantly higher levels than in MGUS. We also have shown that germinal center activation of MYC does not cause MM in a mouse strain that rarely develops spontaneous MGUS. It appears that increased MYC expression at the MGUS/MM transition usually is biallelic, but sometimes can be monoallelic if there is an MYC rearrangement. Our data suggest that MYC rearrangements, regardless of when they occur during MM pathogenesis, provide one event that contributes to tumor autonomy.
INTRODUCTION
The dysregulation of MYC by a chromosomal translocation to one of three immunoglobulin (IG) loci (IGH, IGK, IGL (immunoglobulin heavy chain, kappa, lambda genes)) is a nearly invariant and probably primary event in murine plasmacytoma and human Burkitt's lymphoma tumors. 1, 2 The translocation is thought to be mediated by an error in one of three B-cellspecific DNA modification processes (V(D)J recombination, IGH switch recombination, somatic hypermutation), 3 which repositions MYC near the intronic and/or 3 0 IG enhancers. The nontranslocated MYC usually is not expressed or expressed at very low levels, as expected for the corresponding non-transformed cell. 4, 5 Multiple myeloma (MM), a postgerminal center tumor with a phenotype that is similar to terminally differentiated long-lived bone marrow plasma cells, usually is preceded by a premalignant MGUS (monoclonal gammopathy of undetermined significance) tumor. 6, 7 Similar to MGUS, early stages of MM have only a small fraction of cycling cells. However, the fraction of cycling cells increases during progression, and especially as the tumor extends to extramedullary locations, including secondary plasma cell leukemia (PCL). Virtually all MM cell lines (MMCLs) are derived from PCL or extramedullary MM tumors. 8 Previously, we used metaphase fluorescence in situ hybridization (FISH) analyses to show that complex rearrangements involving MYC (rarely MYCN or MYCL) were present in about 80% of MMCLs and nearly 50% of advanced MM tumors. [9] [10] [11] Avet-Loiseau et al. 12 reported that interphase FISH identified MYC rearrangements in 16% of newly diagnosed MM tumors and 3% of MGUS tumors. Others reported that 8 of 13 patients with PCL had 244K comparative genomic hybridization (CGH) abnormalities that targeted or were close to MYC, with only 4 of these detected by interphase FISH analyses. 13 Strikingly, a substantial fraction of MYC rearrangements in MM do not involve IG sequences. 10, 11, [13] [14] [15] Similarly, MYC rearrangements occurring during progression of B lymphoma sometimes do not involve IG loci. [16] [17] [18] Taken together, these results suggest that MYC rearrangements in MM are mostly late progression events. However, gene expression profiling and immunohistochemistry studies show that MYC RNA expression is significantly increased in MM tumors compared with MGUS tumors. [19] [20] [21] Moreover, activation of an MYC transgene in germinal center B cells results in a nearly universal occurrence of MM in an MGUS-prone mouse strain that rarely develops MM. 19 In the present study, we used a combination of molecular approaches for 238 MM tumors and a panel of 53 MMCLs to determine the prevalence of MYC rearrangements and corresponding MYC expression (RNA levels and mono-vs biallelic expression) in tumors and MMCLs with differing molecular phenotypes. We also characterized MYC rearrangement breakpoints in an attempt to identify non-IG sequences that are responsible for dysregulating MYC in MM. Finally, we have examined the consequences of activating an MYC transgene in the germinal center B cells in a mouse strain that rarely develops MGUS.
MATERIALS AND METHODS

Patient selection
Patients with smoldering multiple myeloma (SMM) (9) , untreated PCL (3), untreated symptomatic MM (108) and previously treated MM (118) were diagnosed according to the established criteria 22 and were included in the Multiple Myeloma Research Consortium (MMRC) Genomics Initiative if more than two million CD138-selected bone marrow cells were available for analysis (B1/3 of submitted samples).
Comparative genomic hybridization
The Agilent 244K CGH raw data was downloaded from the Multiple Myeloma Genomics Portal (http://www.broad.mit.edu/mmgp), and segmented using circular binary segmentation (Bioconductor, www.bioconductor.org). The integrated copy number for the region flanking MYC (chr8: 126 000 000-130 000 000) was normalized to two copies. In four patients (MMRC0028, MMRC0172, MMRC0440, MMRC0034), a single probe abnormality in the telomeric amplified region was segmented based on amplification of more than one copy (see Supplementary Figure S3 ). The hyperdiploid index for each patient was calculated as the average chromosome copy number of chromosomes 3, 5, 7, 9, 11, 15, 19 and 21. All genomic coordinates are from hg19.
FISH analyses
Metaphase FISH assays, which used MYC, IGH, IGL, IGK, chromosome painting probes and sometimes other specific probes, were performed on all MMCLs ( Supplementary Table S2 ), as described previously. 10 Interphase FISH assays to identify MYC:IGH and MYC:IGL fusions were carried out on 218 MMRC MM tumors using the cytoplasmic immunoglobulin light chain (cIg-FISH) technique and probes described previously. 10, 23 Fosmid G248P85602G8 (chr4: 71 533 320-71 573 442) encompassing the IGJ enhancer was used in interphase FISH assays to confirm its insertion adjacent to MYC in MMRC0408.
Gene expression profiling
The Affymetrix Hu133Plus2 raw data was downloaded from the Multiple Myeloma Genomics Portal (http://www.broad.mit.edu/mmgp) for the MMRC MM samples and MMCLs and summarized using MAS5. The Hu133Plus2 MAS5 summarized data for normal plasma cells and MGUS GSE5900 was downloaded from NCBI (Bethesda, MD, USA). Each probe set was normalized to the expression of the 75th percentile on the chip, and then to the median across the samples. The proliferation index 24 and UAMS 70 gene prognostic index (GEP70) 25 were calculated as described previously.
MYC polymorphisms to assess allele-specific expression of MYC RNA
Exonic and intronic polymorphisms were determined in the MMCLs and some tumor samples by Sanger sequencing of PCR products generated from different regions of the MYC gene. The expression of MYC polymorphisms was determined using primers that crossed an intron for exonic polymorphisms or total RNA treated with DNase for intronic polymorphisms ( Supplementary Table S2 and Supplementary Table S4 ). Restriction enzyme polymorphisms of genomic variants rs4645958 and rs2070582 were used to analyze allele-specific expression in some MMRC MM tumors (Figure 2c and Supplementary Table S4 ). Additional details are provided in Supplementary Methods.
Monoclonal gammopathy in Vk*MYC mice
Transgenic Vk*MYC mice in C57Bl/6 were crossed for 10 generations into Balb/c. In the Balb/c background, 38 Vk*MYC transgenic mice and 11 wild-type mice were aged and followed for the presence of a monoclonal spike by serum protein electrophoresis every 10 weeks as described previously. 19 
Supplementary Methods
Chromosome conformation capture (3C), enhancer assays, somatic cell hybrids, mate pair libraries, MYC rearrangements from whole genome sequences and other details.
RESULTS
MYC locus rearrangements detected by karyotypic or CGH assays in MMCLs
Fifty-three independent MMCLs were analyzed for MYC locus rearrangements by metaphase FISH assays as described previously. 10 Including two MMCLs that express MYCL or MYCN, MYC rearrangements involving an MYC family member were detected in 42/53 (79%) MMCLs ( Supplementary Tables S1 and  S2 ). Most rearrangements were complex translocations or insertions. The 244K Agilent array CGH platform also detected MYC locus (but not MYCL or MYCN) copy number abnormalities (CNAs) identifying unbalanced rearrangements in 42/53 (79%) MMCLs, including five for which rearrangements were not detected by the karyotypic assays (Figure 1 , Supplementary Table S1 and Supplementary Table S2 ). No MYC locus rearrangements were detected by either assay in 6/53 (11%) of MMCLs. Twenty-eight of the 47 MMCLs with MYC rearrangements repositioned an MYC family member near one of the IG 3 0 enhancer sequences that are included in the FISH probes: 21 with IGH, 5 with IGL and 2 with IGK ( Supplementary Table S2 ). Rearrangements in the remaining 19 MMCLs did not reveal recurrent partner loci.
MYC locus rearrangements detected by interphase FISH and CGH in 238 primary MM tumors
Using publically available 244K CGH data generated by the MMRC from 235 MM and 3 PCL tumor samples, we normalized the copy number of sequences within a 4 Mb region that includes MYC ( Figure 1 ). Recurring patterns of CNA for 101/238 (42%) tumors are similar to what was seen for MMCLs. Using MYC as a reference location, we classified these changes into four groups: MYC segmental gain, telomeric segmental gain that was located mostly in a region 350-500 kb telomeric to MYC, centromeric gain or loss and other telomeric CNA. A summary of these results for 218 MM tumors that also had interphase FISH assays to identify MYC:IGH or MYC:IGL fusions ( Supplementary Table S1 ) is shown in Table 1 . Ectopic MYCN expression (two tumors) or apparent MYC locus rearrangements, detected by CGH and/or FISH assays, were identified in 108/218 (49%) of tumors. There were 33/218 (15%) tumors that had MYC:IGH (11%) or MYC:IGL fusions, with 22 of these tumors also having CNA in the MYC locus. Although only one of the 25 tumors with centromeric CNA had an MYC:IGH or MYC:IGL fusion, approximately 30% of tumors in each of the other three CGH groups had an MYC:IG fusion.
Consistent with previous FISH studies showing that MYC rearrangements sometimes are not present in all tumor cells, [10] [11] [12] we found that an MYC:IG fusion signal was heterogeneous in 6 (23, 26, 46, 64, 80 and 84% of tumor cells) of 33 tumors that had MYC:IG fusion signals ( Supplementary Table S1 ). Nine of the 218 MM tumors had been classified as SMM, an asymptomatic MM tumor with a relatively stable tumor burden that can sporadically progress to symptomatic MM at a rate of about 10% per year. [26] [27] [28] Yet, 5 (55%) of these SMM tumors had MYC locus CNA detected by CGH, with one having an MYC:IGH fusion in 100% of tumor cells, and another having an MYC:IGL fusion in 23% of tumor cells.
MYC rearrangements in MM are associated with increased MYC RNA expression
The mean level of MYC RNA is threefold higher in the 106 MM tumors with an MYC rearrangement than in tumors with no detectable rearrangement (Po0.0001) (Figure 2a and Supplementary Table S3 ). The mean level of MYC RNA was similar Promiscuous MYC rearrangements in myeloma M Affer et al in each of the four groups defined by the different patterns of CNA detected by CGH. In addition, for tumors with MYC rearrangements, the level of MYC expression was not significantly different for tumors with or without MYC:IG fusions. However, the mean level of MYC RNA was significantly higher in MM tumors without a detectable MYC rearrangement compared with MGUS tumors (Po0.0001). Although the mean value of MYC RNA in MGUS tumor cells is significantly higher than in normal bone marrow plasma cells (P ¼ 0.03), it is possible that some of the MGUS tumor samples might have been MM or SMM tumors that were incorrectly classified. 29 Consistent with the low mitotic index of most MM tumors, a proliferation index based on the expression of 12 genes was only marginally increased in MM vs MGUS vs normal bone marrow plasma cell samples, despite the substantial differences in MYC RNA (Figure 2b ). 24 Although the mean proliferation index is substantially higher in MMCLs compared with MM tumors (Figure 2b ), MYC RNA is not significantly different in MMCLs compared with MM tumors (Figure 2a ). Similar to MM tumors, the mean level of MYC RNA was not significantly different for MMCLs with MYC:IG rearrangements compared with MMCLs with MYC rearrangements not involving an IG locus ( Supplementary Table S3 ).
Allele-specific MYC expression is correlated with rearrangements detected by FISH or CGH Previously, we reported that there was tumor-specific dysregulation of MYCL, MYCN or only one MYC allele in 13 informative MMCLs, all with MYC rearrangements. 9, 11 We now have results for nine additional MMCLs (Figure 2c and Supplementary Table S2 ). Fifteen of 16 MMCLs with MYC locus rearrangements selectively expressed one MYC allele, whereas three of four MMCLs with no detectable MYC locus rearrangement expressed both MYC alleles (P ¼ 0.013). The one MMCL (XG6) with an MYC locus rearrangement that expresses two MYC alleles was unexpected, but is explained by a complex MYC locus rearrangement that appears to have resulted in four copies of MYC, two of which have a somatic mutation (see Supplementary Table S2 , Supplementary Figure S2A and Discussion).
We identified heterozygous germline polymorphisms in 22 primary MM tumors. Ten of 13 tumors with MYC locus rearrangements selectively expressed one MYC allele, whereas seven of nine tumors with no detectable MYC locus rearrangement expressed both MYC alleles (P ¼ 0.027) (Figure 2c and Supplementary Table S4 ). The most likely explanation for the expression of one MYC allele by the two tumors in the latter group is that our FISH and CGH analyses did not detect all MYC locus rearrangements (see Discussion). However, the expression of both The overall copy number for the region for each sample has been normalized to two copies to highlight local changes in copy number. More than 1 log gain is in deep red, more than 1 log loss is in deep blue and copy number within 0.2 log of diploid is in white. The samples are ordered starting with telomeric deletions, segmental telomeric gains (blue arrowhead), segmental MYC gains (black arrowhead) and centromeric deletions and/or gains. MYC alleles in 3 of 13 MM tumors that had an MYC locus rearrangement was more surprising. Perhaps, the MYC locus rearrangement had no effect on MYC expression in some of these tumors. Alternatively, perhaps the rearrangement was present in only a fraction of tumor cells, with either no MYC rearrangement or a different cryptic rearrangement affecting the other MYC allele Regions adjacent to MYC breakpoints in XG6 and L363 are shown, with the location of fragments cloned for enhancer assays indicated. The fragments were located in predicted MM.1S super-enhancers. 35 The relative ability of the various fragments to enhance the transcription of an MYC promoter-driven luciferase construct is shown as relative luciferase activity (RLA) normalized to the activity of the MYC promoter without enhancer. (e) Expression of genes adjacent to putative super-enhancers involved in MYC locus rearrangements during in vitro B-cell differentiation to long-lived plasma cells. The log 2-normalized data from Cocco et al. 23 is shown for the progressive stages of in vitro plasma cell differentiation. In addition to IgH, IgK and IgL (not shown), also IGJ, TXNDC5, FAM46C, FOXO3 and PRDM1 (but not FAM188A or ANKRD55) are markedly upregulated with plasma cell differentiation.
Promiscuous MYC rearrangements in myeloma M Affer et al in other tumor cells, for example, MMRC0006 had an B20% segmental copy number gain (e.g., 2.4 vs 2.0 copies of flanking sequences).
Prevalence of MYC rearrangements is significantly higher in hyperdiploid tumors
We did not detect a significantly different prevalence of ectopic MYCN expression or MYC locus rearrangements in 107 untreated tumors (46%) compared with 111 treated tumors (52%) ( Supplementary Table S5 ). In addition, heterogeneity of MYC:IG fusions occurred with a similar prevalence in untreated tumors (3/15) and treated tumors (3/18). There were two initial proposals for classifying MM tumors into different molecular groups based on gene expression profiling analyses ( Supplementary Table S6 ). The translocation and cyclin D (TC) classification, which identifies IGH translocation groups and patterns of CYCLIN D expression, mostly reflects early pathogenic events common to MGUS and MM. 24, 30 Although mostly similar, the seven molecular group classification includes a PR group of tumors that generally are more proliferative. 31, 32 As summarized in Supplementary Table S6 , there are significant differences in MYC rearrangements for some of the groups: (1) B22% in the TC 11q13 þ 6p21 groups, which have IGH translocations dysregulating CYCLIN D1 or CYCLIN D3, respectively, and in the similar CD1 þ CD2 seven molecular group (Po0.0001); and (2) B63% in the TC D1 þ D1/D2 groups (P ¼ 0.003). These results suggested that the differences in the prevalence of MYC locus rearrangements might be related to hyperdiploidy. We developed a hyperdiploid index, which is the average normalized content of eight odd-numbered chromosomes as determined by CGH analyses ( Supplementary Table S1 and Supplementary Methods). The analysis summarized in Supplementary Table S7 confirms that there is an increasing prevalence of MYC rearrangements that is significantly correlated with an increasing hyperdiploid index even after removing tumors with IGH translocations dysregulating CYCLIN D1 or CYCLIN D3.
Association of MYC rearrangements and molecular prognostic markers
The PR seven molecular group also has an increased prevalence (B70%) of MYC locus rearrangements (P ¼ 0.002) ( Supplementary  Table S6 ), indicating that MYC dysregulation might be contributing to the PR phenotype. Gene expression profiling data on a large number of MM tumors has shown that prognostic predictions can be generated from a proliferation index, and even better with the GEP70. 25, 33 We determined a proliferation index 24 and the GEP70 for the 218 MMRC MM tumors that had been analyzed by FISH and CGH for MYC locus rearrangements ( Supplementary Table S1 ).
In comparing the prevalence of MYC locus rearrangements in the top quintile vs the bottom four quintiles ( Supplementary Table  S8 ), we found a significant difference for both the proliferation index (P ¼ 0.027) and the GEP70 (P ¼ 0.011). Moreover, the GEP70 is significantly correlated with rearrangements in some groups (TC 11q13 þ 6p21, P ¼ 0.001; CD1 þ CD2, P ¼ 0.005; TC D1, P ¼ 0.01; TC 4p16 and MS, PB0.023) but not in others (TC D2, TC D1/D2, TC MAF, LB, HY, PR)) (Supplementary Figure S1 and Supplementary Table S9 ).
MYC rearrangements in MM often involve enhancers but mostly super-enhancers
The structures of rearrangements involving MYC (or MYCL) in 17 MMCLs (Figure 3a , Table 2 and Supplementary Table S10 ) were deduced from a combination of FISH, CGH and mate pair or cloned sequences. We also indicate enhancer elements repositioned near the MYC locus, using published reference data for two cell lines: (1) enhancers and super-enhancers (SEs) in the MM.1S MMCL; 34, 35 and (2) strong enhancers and stretch enhancers identified in the GM12878 lymphoblastoid cell line (LCL), which is phenotypically similar to MMCLs, from ENCODE data on the UCSC genome browser (http://genome.ucsc.edu) 36 and Parker et al. 37 Although the enhancers and SEs in these two cell lines might not apply to all MMCLs and tumors, we have additional evidence suggesting that they generally are applicable. First, most of the putative SEs associated with MYC locus rearrangements (Tables 2 and 3 and Discussion) have been shown to be markedly upregulated with differentiation of B cells to plasma cells (Figure 2e ). 23 Second, we have preliminary DNaseI HS.seq and ChIP.seq (H3K4Me3; H3K27Ac) data for three MMCLs that identify the same enhancers and putative SEs that were identified in the MM.1S MMCL. A description of the structures of rearrangements involving MYC in 12 MMRC MM tumors, which were deduced mostly from whole genome sequences, 38 and also from FISH, CGH and cloned sequences in some cases, is presented in Table 3 and Figure 3b , with additional details in Supplementary Table S11 . [34] [35] [36] Several of these regions were recurrent (NSMCE2, TXNDC5, FAM46C, SNX5, NBEA) in our samples, or found in one of our samples, but two times in the first 29 samples analyzed and publically reported for the CoMMpass project (http://research.themmrf.org) (FOXO3). The JIM3 MMCLs has an MYC rearrangement for which there is no obvious enhancer. In addition, two MM tumors have rearrangements near NBEA with no evidence for enhancers near the breakpoints, but others reported a breakpoint that juxtaposed PVT1 and NBEA in an MMCL. 15 It is possible that there are undetected rearrangements or polymorphisms that might explain these results. Curiously, there are three MMCLs and five MM tumors with two different rearrangements and associated enhancers near MYC. This could reflect passenger events occurring during a complex rearrangement process, or heterogeneity for tumors. Figure 4 summarizes CGH CNA and breakpoints in two recurrent non-IG partner loci. First, it is not surprising that centromeric losses-and perhaps some gains (not shown)-that juxtapose MYC and NSMCE2/TRIB1 enhancers were the most common MYC:non-IG rearrangement, as intrachromosomal rearrangements are more common than interchromosomal rearrangements 39 (Figure 4a ). Second, in addition to the three MMCLs and two MM tumors with MYC:TXNDC5 rearrangements, Figure 4b shows other MMCLs and MM tumors with gains involving TXNDC5, which are clustered among tumors with CGH-detected MYC rearrangements not involving IGH or IGL compared with tumors that have an MYC:IGH or MYC:IGL rearrangement or no rearrangement (P ¼ 0.0001).
Evidence for dysregulation of MYC by rearrangements not involving an IG locus Excluding MYC rearrangements that involve an IGH or IGL locus, allele-specific expression of MYC still is associated significantly with MYC rearrangements for the combined MMCL þ MM tumor samples (P ¼ 0.01) (Figure 2c ). Additional evidence that rearrangements are able to dysregulate MYC includes the following. First, a t(6;22) translocation (chr6: 7 932 054( À )|chr22: 24 572 284( À )), which juxtaposes SUSD2 near an TXNDC5 SE, results in ectopic expression of SUSD2 in the JIM3 MMCL. Second, DNA fragments from putative enhancer regions in intron 4 of NSMCE2 and within ANKRD55 had enhancer activity in transient transfection assays (Figure 2d ). Finally, somatic cell hybrids between several MMCLs and the SP2/0 murine plasmacytoma line showed expression of MYC from EJM and L363 chromosomes having MYC rearrangements, but virtually no expression from chromosomes with germline MYC loci (Supplementary Methods).
DISCUSSION
We identified MYC rearrangements in nearly half of treated or untreated MM tumors.
Avet-Loiseau et al. 12 used interphase FISH to identify MYC rearrangements in 16% of 529 newly diagnosed MM tumors and 10% of 58 relapsed MM tumors. Given the different methodologies, a comparison of the overall prevalence of MYC rearrangements is problematic. However, a direct comparison of the prevalence of MYC fusions with IGH or IGL loci should be informative. We found fusions of MYC with IGH or IGL loci in B15% of treated or untreated MM tumors. By contrast, they found fusions of MYC with IGH or IGL sequences in B4% of either newly diagnosed or relapsed MM tumors. One possible explanation is that the MMRC samples require enough material for analyses and are therefore biased for a larger tumor mass with better ex vivo viability (see Materials and methods), but we also note the use of different IGH and IGL FISH probes.
It is likely that a significant number of MM tumors with rearrangements in the MYC locus have not been detected by the combination of CGH and interphase FISH assays that we used. Supplementary Figure S1 . Additional information regarding these rearrangements is included in Results, and Supplementary Table S10 . (b) The anatomy of MYC locus rearrangements for 12 MMRC MM tumors is presented as described in Figure 3 . Several of the MM tumors have two different rearrangements. Additional information regarding these rearrangements is summarized in Results, Table 2 , and Supplementary Table S11 . (c) cIg-FISH was performed in MMRC0408 demonstrating colocalization of probes for MYC (red) and the IgJ enhancer (green) in the nuclei of plasma cells with light-chain restriction (blue cytoplasmic staining).
Promiscuous MYC rearrangements in myeloma M Affer et al First, 11 of 33 MM tumors with MYC:IG fusions did not have CGH abnormalities (Table 1) . Second, an MYC:IG fusion was found in only 1 of 25 tumors with centromeric losses or gains, but was present in 21 (30%) of the 69 MM tumors in the other three CGH categories ( Table 1 ). Assuming that other partner loci of MYC would mimic MYC:IG fusions, we would predict that about 24 (11%) of the 218 MM tumors would have MYC rearrangements not detected by CGH, for example, the MMRC0387 tumor has an MYC rearrangement detected by whole genome sequencing but not by CGH (Table 3 and Supplementary Table S11 ). Primary IGH translocations involving seven recurrent partners mostly have breakpoints consistent with errors in three B-cell-specific DNA modification processes (IGH switch recombination, somatic hypermutation, V(D)J recombination) that are active during early stages of MM pathogenesis. 6, 10, [40] [41] [42] By contrast, MYC:IGH rearrangements, including all three reported here ( Supplementary Table S10 and Supplementary Table S11 ), usually do not have IGH breakpoints consistent with errors in the three B-cell-specific DNA modification processes that are thought to be inactive in plasma cells or plasma cell tumors. We identified a number of MMCLs and MM tumors with variant MYC:IGH translocations for which the IGH locus, including at least one 3 0 IGH enhancer and the most telomeric VH sequences, is positioned telomeric to MYC. 10, 11, 43 Given that there are insulator sequences centromeric to 3 0 IGH enhancers, 44, 45 we predicted that these translocations would be associated with a deletion of the insulator, or have an inversion so that the insulator was no longer located between MYC and the 3 0 IGH enhancer. 43 Our analysis of the variant MYC:IGH translocation in the LP1 MMCL showed that there is an inversion, confirming our prediction (Supplementary Figure S2B) .
MYC:IGH (45%), MYC:IGL (11%) and MYC:IGK (4%) accounted for 60% of MYC rearrangements in MMCLs, whereas MYC:IGH (24%) and MYC:IGL (8%) accounted for 32% of MYC rearrangements in the MMRC MM tumors ( Table 1 , Supplementary Table S1 and Supplementary Table S2 ). The fraction of MYC rearrangements involving IGH or IGL is significantly higher (P ¼ 0.007) in MMCLs than in the MM tumors. This is somewhat surprising given that the mean level of MYC RNA expression (and the GEP70 for tumors) is not significantly different for MMCLs or MM tumors with MYC:IG vs MYC:non-IG rearrangements. Although there is evidence for recurrent non-IG partners (see above), there is not yet enough information to reveal the full repertoire of partner loci involved in MYC rearrangements in MM. However, there are at least four (NSMCE2/TRIB1, TXNDC5, FAM46C, FOXO3)-perhaps six (SNX5, NBEA)-loci that are frequent partners. Significantly, MYC 
MMCLs
Description of MYC locus structural variation LP1 FISH analyses have shown that variant IGH translocations involving MYC have 3 0 IGH SE (Ea) and VH telomeric sequences located telomeric to MYC. 10, 11 The chr8 breakpoint is B390 kb downstream of MYC and the chr14 breakpoint is located at the telomeric end of the Ea1 SE, but with chr14 sequences proceeding in a centromeric direction away from the breakpoint as a result of an inversion within the IGH locus that was detected from mate pair sequences (SF1 and Discussion) H929
A deletion of 8:126 344 414-128 713 154 positions MYC B100 kb from an SE and other enhancer elements in intron 4 of NSCME2 XG6
Has a deletion 8 breakpoint 126 324 9774|o128 737 494, and also a second breakpoint downstream of MYC: 128 775 3734|o126 287 002. There is a copy number gain by CGH related to these breakpoints, that is, 126 287 002-126 324 977 (B38 kb) and 128 737 494-128 775 373 (B38 kb). These data indicate that MYC is flanked by an SE and other enhancer sequences located in intron 4 of NSMCE2 and vice versa, with several copies of both regions on the rearranged chromosome (see SF1) INA6
der(1) of a reciprocal t(1;8) translocation has a chr1 breakpoint within or just beyond FAM46C, so that the downstream SE region is near the breakpoint. MYC is predicted to be B1209 Mb from the chr8 breakpoint, but numerous intrachromosomal rearrangements in the MYC locus suggest that MYC might be much closer to the breakpoint U266
A 77 Mb inversion on 1p has breakpoints located 7 kb downstream of MYCL and in the 3 0 -untranslated region of FAM46C; MYCL is repositioned near the SE region downstream of FAM46C KMS18
An interchromosomal translocation has a chr6 breakpoint B50 kb upstream of TXNDC5 so that SEs associated with TXNDC5 are predicted to be located B500 kb upstream of MYC OCIMY1
A complex translocation shows that B15 kb of chr6 sequences that contain an SE region located downstream of TXNDC5 are positioned B560 kb downstream of MYC; the other end of the chr6 segment is juxtaposed to chr22, with the breakpoint located B530 kb centromeric to the 3 0 IGL SE ARP1
This der (8) Promiscuous MYC rearrangements in myeloma M Affer et al rearrangements involving 1p13, 6p21, 6q21 and 13q14 are recurrent in previous karyotypic analyses. 10, [46] [47] [48] [49] One of the most striking findings from the CGH analyses was that 30 MM and 4 MMCLs had a segmental telomeric gain that was located about 350-500 kb telomeric to MYC (Figures 1 and 4c ). Ten of the 30 MM tumors had an MYC:IG fusion or insertion of an IGJ SE (Figure 3c ), and one (VP6) of the 4 MMCLs tumors had an insertion of 3 0 IGH enhancer sequences between the duplicated chr8 sequences that were identified by CGH. The EJM MMCL had a 58 kb region and AHNAK stretch enhancer from chr11 inserted between the duplicated sequences on chr8. However, two HMCL (KP6, XG2) had only a tandem duplication of sequences in this region. The targeting of this region for duplication is consistent with chromosome conformation capture (3C) experiments, which showed that an MYC promoter fragment containing a CTCF-binding site interacts preferentially with a fragment containing a CTCFbinding site that is located near several enhancers, including a stretch enhancer (Figure 4d ). It seems possible that this interaction facilitates the interaction of MYC with enhancer sequences repositioned near this region. Regarding the two MMCLs with tandem duplications in this region without insertion of an exogenous enhancer, we can only speculate that the duplication somehow unmasks or creates a functional enhancer element in this region.
Most MYC rearrangements in MMCLs and tumors reposition MYC near a putative SE or stretch enhancer. 34, 35, 37 That is, for MMCLs, 11/14 not having an MYC:IG rearrangement ( Table 2) but 39/42 including MMCLs with MYC:IG rearrangements ( Supplementary Table S2 ); and for MM tumors, 7/11 not having an MYC:IG rearrangement (Table 3 ), but 40/44 including tumors with MYC:IG rearrangements (Table 1 ). Most rearrangements not involving an MM.1S SE appeared to involve credible MM.1S or LCL enhancer elements that might have properties of SE in specific MMCLs or MM tumors, possibly as a consequence of tumorspecific chromatin marks, and perhaps related to tumor-specific MYC locus rearrangement. It is not clear why there is markedly non-random targeting of MYC rearrangements to a limited number of partner loci, most of which contain SE regions. Although we are unable to answer this question, it is possible that the recurrent involvement of the FAM46C SE is selected because this rearrangement can inactivate one copy of the FAM46C tumor suppressor gene while also dysregulating MYC. 38, 50 Nonetheless, the identification of these partner loci suggests that they will help us to identify other genes (e.g., SUSD2:TXNDC5 SE) that are dysregulated when repositioned near these regions in plasma cell tumors. The activation of MYC by rearrangements that mostly reposition it near an SE provides clear evidence that genomic rearrangements in other kinds of tumors are likely to hijack a subset of cell-and tumor-specific SE that will dysregulate expression of oncogenes. 34, 35 Increasingly, it has become apparent that dysregulation of MYC (less often MYCN or MYCL) is an essential event in MM. 19, [51] [52] [53] Previous results indicated that germinal center activation of an MYC transgene caused progression of MGUS to MM in an MGUS-prone mouse strain, a conclusion that is supported by new results showing that the same transgene does not cause MM in a A 34 kb fragment, which contains an SE element that is located immediately 5 0 of IGJ, is inserted into a region B500 kb downstream of MYC; the insertion is flanked by a duplicated chromosome 8 sequence of B61 kb MMRC0375
An inversion has juxtaposed a sequence in intron 4 of NSMCE2 (chr8:126 359 255) with a sequence B280 kb downstream of MYC, but anB237 kb deletion immediately downstream of MYC suggests that the inversion breakpoint would be located B40 kb downstream of MYC, that is, very near an SE and other enhancer elements in intron 4 of NSMCE2 MMRC0421
This complex rearrangement is manifested by a breakpoint B69 kb downstream of MYC and B120 kb downstream of TRIB1 (both strands with the same orientation), suggesting that stretch enhancers B75 kb downstream of the breakpoint could dysregulate MYC MMRC0392
There are two MYC rearrangements in this tumor, suggesting the possibility of two clones with different MYC rearrangements: (1) a deletion repositioning intron 4 of NSMCE2 and its SE and enhancer elements within B20 kb of MYC; and (2) an interchromosomal rearrangement that repositions an SE upstream of TXNDC5 so that it would be B50 kb upstream of MYC MMRC0406
There were two different interchromosomal breakpoints involving MYC. The first occurs within a chr6 SE region upstream of TXNDC5 so that it would be located B32 kb upstream of MYC. The second occurs in a chr20 intergenic region between SNX5 and BANF2 that contains an SE and other enhancer sequences, which would then be located B100 kb downstream of MYC. A copy number gain of chr8 sequences between these two breakpoints suggests, but does not prove, that both rearrangements occur in the same tumor cell MMRC0425
The interchromosomal breakpoint also occurs on chr20 between SNX5 and BANF2 so that the intergenic SE and other enhancers are predicted to be located B700 kb downstream of MYC MMRC0417
There were two different interchromosomal breakpoints involving MYC. The first has a chr6 breakpoint B100 kb downstream of FOXO3, which encompasses a strong SE, and B15 kb downstream of LINC00222, which also is associated with several enhancer elements; the chr8 breakpoint is B25 kb upstream of MYC. The second has a chr7 breakpoint within the 5 0 end of GLCCI1, which has enhancer elements located within and upstream of its promoter region; the chr8 breakpoint is B80 kb downstream of MYC. There is a copy number gain of chr8 sequences between these two breakpoints, consistent with-not proving-the fact that they are on the same derivative chromosome in the same tumor cell MMRC0387
This apparent reciprocal translocation has a chr8 breakpoint B370 kb downstream of MYC and a chr4 breakpoint at the 5 0 end of C4orf45, suggesting that MYC could be dysregulated by the enhancer sequences in the C4orf45 promoter MMRC0343
There is a chr8 gain (including MYC) between two breakpoints. The chr21 breakpoint is immediately downstream of HSF2BP, with an ENCODE LCL enhancer predicted to be located B65 downstream of MYC. The chr5 breakpoint is B8 kb upstream of HNRNPAB and ENCODE LCL enhancer elements associated with this gene, and also with an ENCODE LCL insulator separating the enhancer elements from the breakpoint MMRC0319
There are two MYC rearrangements. The first is a reciprocal translocation with a chr8 breakpoint B33 kb downstream of MYC and a chr13 breakpoint B240 kb upstream of NBEA1, but only a combination of ENCODE LCL weak enhancers and insulators in the promoter regions of NBEA transcripts. The second is a chr8 deletion that repositions MYC near enhancers in the PVT-1 locus MMRC0376 This is a reciprocal t(8;13) translocation that is similar to the one in MMRC0319, but with the chr8 breakpoint located B726 kb downstream of MYC and the chr13 breakpoint located B248 kb upstream of NBEA The latter is centered in a region that preferentially associates with the MYC promoter, and also contains a cluster of MM.1S enhancer sequences and GM12878 stretch enhancers. (d) Interaction of an MYC promoter with distal telomeric sequences. 3C experiments show a preferential interaction of an MYC promoter fragment that contains a CTCF-binding site with a fragment, which is located B500 kb telomeric of MYC, and that also contains a CTCF-binding site. The JJN3 MMCL has an MYC:IGH rearrangement, but the U266 MMCL has a MYCL rearrangement and expresses virtually no MYC. mouse strain that rarely develops MGUS (Figure 5a ). The increased MYC expression at the MGUS/MM transition can be biallelic, or monoallelic, if there is an MYC rearrangement. Given the evidence for heterogeneity of MYC rearrangements in about 18% of treated or untreated MM tumors with MYC:IGH or MYC: IGL rearrangements, it is clear that the prevalence of MYC rearrangements increases during tumor progression. 10, 12, 54 Initially, we had proposed that most MYC rearrangements were a late progression event. However, in view of a high and similar prevalence of MYC rearrangements in untreated and treated MM tumors, and in SMM tumors, it now seems possible that some of these rearrangements occur early (Figure 5b ). One caveat is that the MMRC MM tumors analyzed may be skewed toward more advanced stages of disease (see Materials and methods and Supplementary Table S14 ).
Regardless of whether MYC rearrangements occur at early or late stages of pathogenesis, MYC rearrangements may provide one of several critical events contributing to increased autonomy (perhaps one manifestation being decreased expression from the non-rearranged MYC allele) and a more aggressive phenotype. Although we do not have sufficient survival data for individuals from whom the MMRC MM tumors were derived, we determined that the GEP70, which is correlated strongly with low patient survival, 25 is significantly increased in tumors with MYC rearrangements (Po0.0001), but only in some molecular types of MM (Results, Supplementary Figure S1 and Supplementary Table S9 ). However, Avet-Loiseau et al. 55 reported that MYC rearrangements were not associated with survival, so that the prognostic significance of MYC rearrangements remains to be clarified. Given the uncertainty of the prevalence of MYC rearrangements at early vs late stages, it is important to achieve a better understanding of when MYC rearrangements occur in different kinds of MM tumors, and how they impact MM pathogenesis and prognosis. 
